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Partnership, the Transatlantic Free Trade Area/Transatlantic Trade 
and Investment Partnership, and the Trade in Services Agreement 
has bypassed the momentum created by the WIPO Development 
Agenda in addressing the reformation of the dominant discourse of 
Patent Regime focusing sideling the “access” issues of public health.
The central issue is that of the old patent regime, which advo-
cates that “monopoly” rights lead to “innovation” and thereby will 
address the public health issues versus the counterview that “monop-
oly” rights itself is not a linear solution to public health but needs to 
use it as an “appropriate intervention tool” to spur innovation. Thus, 
the “monopoly” question needs to be subjugated to the final question 
of “access” of drugs for all for a better public health.
This article aims to track and disseminate the recent developments 
on the question of the access versus monopoly debate from the emerg-
ing agreements outside the TRIPS and Development Agenda dialogue 
and its impact on the future of public health.
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Background: According to the Declaration of Helsinki, as well as 
the Statement on Public Disclosure of Clinical Trial Results of the 
World Health Organization, every researcher has the ethical obliga-
tion to publish research results on all trials with human participants 
in a complete and accurate way within 12 months after the end of 
the trial.1,2 Nevertheless, for several reasons, not all research results 
are published in an accurate way in case they are released at all. This 
phenomenon of publication bias may not only create a false impres-
sion on the reliability of clinical research business, but it may also 
affect the evidence of clinical conclusions about the best treatments, 
which are mostly based on published data and results.
Objectives: The aim of this article was to present different types of 
publication bias with regard to authors, peer reviewers, and editors. 
Already implemented approaches for a reduction in the publication 
bias phenomenon will be provided to strengthen confidence in the 
clinical research business.
Methods: Literature on publication bias for this narrative review 
article was identified by searching the PubMed database using the 
key words “publication bias in clinical research.” The search was 
limited to articles available as free full-text papers with publication 
dates later than 2010. Likewise, a Google search with the same key 
words was performed.
Results: Based on the reviewed literature, publication bias can be 
classified into 3 different types. The first type can be defined as pub-
lication bias, which occurs through the author before the submis-
sion of the manuscript to a journal in terms of nonpublication or 
incomplete publication of negative research results. Both other types 
describe publication bias after submission of the manuscript to a 
journal. In these cases, either the peer reviewer or the editor of a 
journal can cause bias during the publication process. For reducing 
the publication bias phenomenon in clinical research, most of the 
leading journals meanwhile insist on a registration of the study in 
public registries such as clinicaltrials.gov as a condition for successful 
publication.3 Also, the implementation of a blinded peer-reviewing 
process, in which the peer reviewer will do the review without know-
ing any author details, represents an improvement in publication bias.
Conclusions: The phenomenon of publication bias not only occurs 
before submission of manuscripts, but it may also happen after sub-
mission to a journal.4 It still forms an issue in discussions about 
evidence-based medicine. Thus, publication of trial results is required 
by internationally applicable guidance, and ongoing discussions are 
needed to keep attention by stakeholders to achieve a greater trans-
parency in the area of clinical research.
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The United States Department of Health and Human Services is 
charged with improving the health, safety, and well-being of all 
Americans. Since 2004, when former President George W. Bush 
set a goal for all Americans to have an electronic health record by 
2014, the Office of the National Coordinator (ONC) for Health 
Information Technology under the Department of Health and Human 
Services has been steadily making progress. By moving from paper 
to electronic health records, many benefits can be achieved, includ-
ing enhanced patient safety, improved care coordination, increased 
patient participation, practice efficiencies, and cost savings. The 
vision for 2024 as stated in an ONC report is an “interoperable 
health information technology (IT) ecosystem that makes the right 
data available to the right people at the right time across products 
and organizations in a way that can be relied upon and meaningfully 
used by recipients.”1
At the heart of a highly functional interoperable health infor-
mation technology ecosystem is accurate patient identity. Ensuring 
patient identity is essential for patient safety and quality of care. 
Accurate patient identification is the foundation for successfully link-
ing patient records within an integrated health care delivery system 
and across the health care ecosystem.2 The first of 5 building blocks in 
achieving ONC’s vision for 2024 tackles the need for standards that 
address essential services for interoperability, which include methods 
to accurately match individuals, providers, and their information 
across data sources.3 Furthermore, health care organizations need to 
ensure that a robust information governance program is implemented 
to address patient identity integrity.
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Emerging markets are considered nowadays the “Promised Land” 
for pharmaceutical industries. Although a clear-cut definition of 
these markets is not yet available, Forbes magazine along with 
other economists define them as developing prosperous countries. 
In these countries, an investment is expected to result in higher 
income despite the high risks. Qualifying a market as emerging is 
not solely based on the country’s economic status but rather on a 
series of criteria making the definition relative to each. Jim O’Neill, 
retired chairman of Goldman Sachs Asset Management, coined 
the names of the 2 leading economies of emerging markets into 
2 acronyms. BRICS countries (Brazil, Russia, India, China, and 
later South Africa) emerged first and were followed years later by 
MIST countries (Mexico, Indonesia, South Korea, and Turkey) as 
the second wave of tiers countries joining emerging markets. In the 
last 5 years, sales of pharmaceuticals in BRICS and MIST mar-
kets doubled, reaching a share of ~20% globally. This shift stems 
from the huge populations of the concerned societies, an increasing 
prosperity, and life expectancy. In addition, companies are suffering 
from a flattened growth rate in developed markets, the expiration 
of > 40% of patents leading to the up-selling of cheaper generic 
drugs, and the existing tight regulations. However, Big Pharma needs 
to be cautioned regarding these emerging markets. Pharmaceutical 
companies wanting to expand in these emerging opportunities have 
to tailor their strategies according to the developing pace of each 
country. These communities are in need of drugs against infectious 
and communicable diseases such as sexually transmitted diseases. 
They are ready-to-exploit territories for the innovative products of 
pharmaceuticals. However, with the increase in wealth and longevity, 
a change of lifestyle is slowly taking place accompanied by a shift in 
the disease trends. A disproportionately fast rise in the incidence of 
noncommunicable diseases such as cardiovascular illnesses, diabetes, 
and cancers is noticed in emerging markets, mimicking the pattern of 
their Western counterparts. The incidence of diabetes and oncologic 
diseases is expected to grow by ≥ 20% in the next 5 years. This could 
be viewed as a mixed blessing, as pharmaceutical industries will 
be able to sell their global products in these new markets as well. 
Industries face challenges to conquer emerging markets grouped 
into 3 categories: infrastructure development, cost-containment poli-
cies, and value-driven drug evaluation. To overcome these hurdles, 
new strategies need to be adopted by pharmaceutical companies. 
Adequate tailoring and gain in market are among the top strategies 
to be considered.
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Background: In hospitals, clinical data are often scattered across 
multiple databases and application systems due to decentralized clini-
cal information system architectures. Consequently, the reuse of once 
collected data for secondary purposes as data analytics and data 
mining is considered a challenging task.1 Enterprise Data Warehouses 
(EDW) have been established at several medical centers to overcome 
typical obstacles to data reuse such as proprietary data models, ter-
minologies, lack of governance, and more. However, the complexity 
and high rate of change of the clinical domain and medical data 
cause high costs for maintenance of data models and the provision 
of data to researchers.2 Detailed Clinical Models might help to better 
manage these domain-specific challenges by introducing formal and 
computable methods to represent clinical content models to data 
warehousing.3 One example of a Detailed Clinical Model approach 
is openEHR, a specification of an open, interoperable electronic 
health record.4 Although the use of openEHR in the context of a 
health information exchange is well established, there is still a lack 
of evidence regarding its feasibility to represent and integrate legacy 
data into EDWs.
Methods: We chose the domain of intensive care medicine to investi-
gate if openEHR can meet a diverse set of requirements to represent 
and help integrate clinical data that are stored in application systems. 
At Hannover Medical School, 2 independent patient data manage-
ment systems (COPRA and m.life) are incorporated at the intensive 
care wards. We identified a test set of 8 clinical concepts that are 
commonly used in these systems: blood pressure, body temperature, 
pulse, heart rate, indirect oximetry, Braden Scale, Glasgow Coma 
Scale, and ventilation. For each of these measurements, we intended 
to obtain an openEHR Archetype (a formal content model of a clini-
cal concept) or to create a new one. Subsequently, Archetypes were 
used to create a Template, which can be thought of as a use case-
specific document. For the task of data integration and mapping, we 
used a combination of Microsoft SSIS, Altova MapForce 2014, and 
the Template Document Schema approach.5
Results: We obtained 7 Archetypes from the Clinical Knowledge 
Manager, the public content model repository of the openEHR 
Foundation. Because no ventilation Archetype was available at the 
time of this work, we created a new Archetype. We found it possible 
to map most types of legacy data from the given application systems 
to openEHR Templates. The representation and mapping of Braden 
Scales and Glasgow Coma Scales data were straightforward. By con-
trast, the mapping of continuous sensor data (eg, blood pressure 
measurements generated by sensors) required the arbitrary segmenta-
tion of values into multiple documents. For this purpose, we chose 
a 24-hour interval. When integrating ventilation data, we found a 
high number of corresponding variables in the source systems (~300). 
Because available resources were limited, we decided to create a first 
draft version of the ventilation Archetype that only represents data 
elements of the most important parameters. In coordination with a 
clinical expert, 30 data items were identified and then modeled in 
the archetype.
